Mohammed Fawziah M A, Rezaee Khorasany Ali Reza, Mosaieby Elaheh, Houshmand Massoud
Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, Kuwait.
Department of Pharmacodynamy and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Diagn Pathol. 2015 Jul 19;10:115. doi: 10.1186/s13000-015-0337-6.
Colorectal cancer is the third most common type of cancer in men and women and the second leading cause of cancer-related deaths in the United States and UK. Colorectal cancer is strongly related to age, with almost three-quarters of cases occurring in people aged 65 or over. Pre-symptomatic screening is one of the most powerful tools for preventing colorectal cancer. Recently, the use of mitochondrial tRNA genes mutation or polymorphism patterns as a biomarker is rapidly expanding in different cancers because tRNA genes perform several functions including processing and translation which are essential components of mitochondrial protein synthesis. The aim of the present study was to find out the association of mitochondrial A12308G alteration in tRNA(Leu(CUN)) in colorectal cancer and its usage as a new biomarker screening test.
A tumor tissues from 30 patients who had colorectal cancer were selected randomly. The A12308G alteration in tRNALeu (CUN) was screened in the 30 colorectal tumor tissues. For comparison, 100 blood samples of healthy controls using PCR-sequencing methods were selected and the following results were found.
The A12308G, a polymorphic mutation in V-loop tRNA(Leu(CUN)), was found in 6 Colorectal tumor tissues and 3 healthy controls. A statistical significant difference was found between cases and control regarding the association of the A12308G mutation with the colorectal tumor (P < 0.05).
The A12308G, a polymorphic mutation in V-loop tRNA(Leu(CUN)), could be considered as pathogenic mutation in combination with mitochondrial external conditions and other mitochondrial genes in developing different diseases especially cancers and could be used as one of the diagnostic tool. Also it seems that maybe there is relevance between A12308G mutation and other mutations that it can cause various phenotypes.
结直肠癌是男性和女性中第三常见的癌症类型，在美国和英国是癌症相关死亡的第二大主要原因。结直肠癌与年龄密切相关，近四分之三的病例发生在65岁及以上的人群中。症状前筛查是预防结直肠癌最有效的工具之一。最近，线粒体tRNA基因突变或多态性模式作为一种生物标志物在不同癌症中的应用正在迅速扩展，因为tRNA基因执行多种功能，包括加工和翻译，这些是线粒体蛋白质合成的重要组成部分。本研究的目的是找出结直肠癌中tRNA(Leu(CUN))线粒体A12308G改变及其作为一种新的生物标志物筛查试验的用途。
随机选取30例结直肠癌患者的肿瘤组织。对30例结直肠癌肿瘤组织进行tRNALeu (CUN)的A12308G改变筛查。为作比较，选取100份健康对照者的血样采用PCR测序方法，得到以下结果。
在6例结直肠癌肿瘤组织和3例健康对照者中发现了V环tRNA(Leu(CUN))中的多态性突变A12308G。在病例组和对照组之间，A12308G突变与结直肠癌的关联存在统计学显著差异（P < 0.05）。
V环tRNA(Leu(CUN))中的多态性突变A12308G，在与线粒体外部条件和其他线粒体基因结合时，在引发不同疾病尤其是癌症的过程中可被视为致病突变，并且可作为诊断工具之一。此外，A12308G突变与其他可能导致各种表型的突变之间似乎可能存在关联。
